undamentalytics Newsletter
Sign in

Taysha Gene Therapies, Inc. key statistics and ratios

In fiscal 2025, Taysha Gene Therapies, Inc. had return on equity of -68.5%, an operating margin of -1130.6%, debt equal to 20.3% of equity and a current ratio of 12.23. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Operating margin<−999%−468.8%<−999%<−999%<−999%
Net margin<−999%−722.1%<−999%<−999%<−999%
Free-cash-flow margin<−999%−497.6%−979.2%−960.1%<−999%
Return on equity——−121.9%−68.5%−47.2%
Return on assets−131.5%−74.6%−53.6%−43.3%−36.8%
Asset turnover0.020.100.050.040.01
Current ratio1.544.085.4212.2317.76
Debt to equity>999%54.1%61.4%20.3%12.9%
Interest cover (operating income ÷ interest)n/mn/mn/mn/mn/m
R&D as % of revenue>999%367.5%792.0%884.1%>999%
Capital spending as % of revenue824.1%25.0%4.5%7.6%6.9%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

5 of 7 checks passed · June 30, 2026
What it owns · $470m
Short-term assets $461mLonger-term assets $9m
What it owes, and who funded it · $470m
Short-term liabilities $26mLonger-term liabilities $57mShareholders' equity $387m
  • Short-term assets cover short-term liabilities $461m of assets due within a year against $26m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $461m short-term assets against $57m of longer-dated liabilities.
  • More cash than debt $455m of cash against $49m of debt.
  • Debt below 40% of shareholders' equity Debt is 13% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 39% to 13% over five years.
  • A year's operating cash flow covers at least 20% of debt −$132m of operating cash flow against $49m of debt.
  • Operating profit covers interest at least five times over Operating income of −$153m against $42,000 of interest.

From Taysha Gene Therapies, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: IMRN vs TSHAIVA vs TSHAANL vs TSHACGON vs TSHA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Taysha Gene Therapies, Inc.